Free Trial
NASDAQ:SLN

Silence Therapeutics Q2 2025 Earnings Report

Silence Therapeutics logo
$5.64 +0.10 (+1.71%)
As of 11:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Silence Therapeutics EPS Results

Actual EPS
-$0.54
Consensus EPS
-$0.27
Beat/Miss
Missed by -$0.27
One Year Ago EPS
N/A

Silence Therapeutics Revenue Results

Actual Revenue
$0.22 million
Expected Revenue
$8.50 million
Beat/Miss
Missed by -$8.28 million
YoY Revenue Growth
N/A

Silence Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
7:30AM ET

Upcoming Earnings

Silence Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 13, 2025

Silence Therapeutics Earnings Headlines

HC Wainwright Reaffirms Buy Rating for Silence Therapeutics (NASDAQ:SLN)
This is the “End of Tesla” as we know it…
Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla call alone could have made readers 21 TIMES THEIR MONEY, if they listened to his recommendation. Don't miss his next big prediction.tc pixel
See More Silence Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Silence Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silence Therapeutics and other key companies, straight to your email.

About Silence Therapeutics

Silence Therapeutics (NASDAQ:SLN) plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism. Both programs have advanced through early clinical stages, generating proof-of-concept data. Silence also maintains a portfolio of preclinical research programs targeting liver-related diseases, while exploring strategic collaborations to broaden the reach of its RNAi platform across multiple therapeutic areas.

Founded in the United Kingdom and headquartered in London, Silence Therapeutics operates research and development facilities in Europe and the United States. The company has navigated the evolving RNA therapeutics landscape since the early 2000s, transitioning from discovery research into clinical development. Under the leadership of Chief Executive Officer Eric M. Rose, Silence continues to advance its pipeline with the objective of delivering novel RNAi medicines to patients with high-unmet medical needs worldwide.

View Silence Therapeutics Profile

More Earnings Resources from MarketBeat